programme - ilca 2020 · 2020. 9. 11. · david rep áraz (spain) • p ... riccardo lencioni, md...

www.ilca2020.org

Programme Final Programme

http://www.ilca2020.org

I ILCA VIRTUAL CONFERENCE 20202

Table of Contents

Letter of Welcome ....................................................................................... ..... 3

Programme at a Glance .................................................................................... 4

On demand Sessions from 7 September ....................................... 4

Friday, 11 September 2020 ........................................................... .. 6

Saturday, 12 September 2020 ........................................................ 9

Sunday, 13 September 2020 ........................................................... 12

Practicalities ................................................................................................. ..... 14

Sponsors, Media and other Partners ........................................................... . 15

Partner Symposia .............................................................................................. 16


WeclomeLetter of WelcomeDear ILCA members, colleagues, and friends,

It is our great pleasure to invite you to attend the Virtual 14th Annual Conference of the International Liver Cancer Association (ILCA) from 11 to 13 September 2020.

Our community will gather for three days of sharing knowledge, of scientific learning and intensive networking around the latest advances in liver cancer research, basic translational and clinical research.

ILCA continues to develop new programmes and initiatives and will again bring together the most eminent liver cancer experts from around the globe with the goal of improving the prevention, diagnosis, treatment and care of patients.

The programme that the Governing Board has put together will provide you with an outstanding educational experience. We have developed a range of new session formats with exciting content to encourage knowledge sharing between physicians, researchers, young investigators and partners from all over the world.

We look forward to welcoming you all virtually as we work together to advance liver cancer science and care to offer true hope to patients.

Warm regards,

On behalf of the ILCA Governing Board

Bruno Sangro, MD, PhD

ILCA President

Augusto Villanueva, MD, PhD

ILCA Executive Secretary


SEQUENCING AND STRATIFICATION OF SYSTEMIC THERAPY IN HCC SYMPOSIUMCHAIRS: LORENZA RIMASSA, MD (ITALY), R. KATE KELLEY, MD (USA)

The Growing Landscape of Systemic Therapies for Advanced HCC• A New Choice: Selecting Among Evidence-Based 1st Line Therapies for Advanced HCC

Ann-Lii Cheng, MD, PhD (USA)• The Second Line in a Dynamic Landscape

Stephen Chan, MD, PhD (Hong Kong)• The evolving role of checkpoint inhibitors in advanced HCC

Anthony El-Khoueiry Chan, MD (USA)

Expanding the Reach of Systemic Therapy in HCC• Novel Molecular Targets, Agents and Biomarkers for HCC

Josep Maria Llovet, MD, PhD (Spain/USA)

Endpoints for Systemic Therapy Trials in Advanced HCC: Should Overall Survival be the Only Gold Standard in Expanding Treatment Landscape?• PRO: OS remains gold standard.

Maria Reig, MD, PhD (Spain)• CON: Surrogate endpoints are acceptable and necessary.

Richard Finn, MD (USA)

Systemic Therapy in Special Populations• Hepatic dysfunction (Child Pugh >A) and Post-transplant

Laura Kulik, MD (USA)• HIV, dialysis, and autoimmune disease

David Pinato MD, MRCP (UK)• Mixed HCC-cholangiocarcinoma

Gregory Gores MD, (USA)

Immunotherapy in Earlier Stages of HCC• HCC Immunotherapy in Earlier Stages of HCC

Bruno Sangro, MD, PhD (Spain)

SYMPOSIUM: CANCER CARE BEYOND ANTI-TUMOR THERAPYCHAIR: BRUNO SANGRO, MD, PHD (SPAIN)

Pshychooncology: Basic Principles applied to liver cancer Maria DieTrill, PhD (Spain)

Management of cancer-treatment related Fatigue and cancer-related cachexia:Combine supportive, palliative, and rehabilitative careFlorian Strasser, MD (Switzerland)

GlanceProgramme at a GlanceON DEMAND SYMPOSIA


GlanceProgramme at a Glance

BASIC SCIENCE SYMPOSIUM: MOLECULAR PATHOGENESIS AND TARGETS IN

CHOLANGIOCARCINOMACHAIR: AUGUSTO VILLANUEVA, MD, PHD (USA)

Pathogenesis and molecular drivers of cholangiocarcinomaGregory Gores, MD (USA)

Novel therapeutic targets in cholangiocarcinoma: Beyond IDHDaniela Sia, PhD (USA)

Biomarkers in cholangiocarcinomaJesper B. Andersen, MD, PhD (Denmark)

ILCA GUIDANCE SYMPOSIUM: SYSTEMIC THERAPY GUIDANCE AND BIOMARKER DEVELOPMENT IN HCC

Systemic Therapy Guidance Tim Meyer, MD, PhD (UK)R. Kate Kelley, MD (USA)

Biomarker Development in HCC GuidanceAugusto Villanueva, MD, PhD (USA)Amit Singal, MD (USA)

SINGLE TOPIC WORKSHOP: MOLECULAR DIVERSITY AND SYSTEMIC TREATMENT FOR HCC AND SURGERY IN THE MANAGEMENT OF HCC: ROLE OF SURGEONS AND OF THE RADIOLOGISTSCHAIR : JEAN-CLAUDE NAULT, MD, PHD (FRANCE)

molecular diversity and systemic treatment for HCCAmaia Lujambio, PhD (USA)Andrew Zhu, MD, PhD (USA)

Surgery in the management of HCC: role of surgeons and the radiologistsRiccardo Lencioni, MD (Italy)Eric Vibert, MD, PhD (France)

ON DEMAND SYMPOSIA


GlanceProgramme at a GlanceFRIDAY, 11TH SEPTEMBER 2020

CEST TIME

15.00 - 16.00 YOUNG INVESTIGATOR SESSIONChair: Morris Sherman, MD, PhD (Canada)

4 oral presentations submitted by young reserachers followed by Q&A time.

• O-01 International, Multicenter Study on The Outcome of Locoregional Therapy Before Liver Transplant for Hepatocellular Carcinoma Extending the Milan Criteria

Helena Degroote (Belgium)

• O-02 Impact of Age on Sorafenib Outcomes in Hepatocellular Carcinoma: An International Cohort Study.

Saur Hajiev (UK)

• O-03 Prospective Intra-Individual Comparison of Contrast-Enhanced Ultrasound with Sulfur Hexafluoride and Perfluorobutane For Diagnosis of Hepatocellular Carcinoma in High-Risk Patients

Hyo-Jin Kang (Republic of Korea)

• O-04 Cabozantinib Enhances the Efficacy and Immune Activity of Anti-Pd1 Therapy in A Murine Model of Hepatocellular Carcinoma

Catherine Willoughby (Spain)

16.05 - 16.35 BEST CLINICAL POSTER SESSION10 Top scored clinical e-Posters presenters will participate on this LIVE Q&A session where participants and specialists will ask poster presenters about findings described in their poster.Chair: Laura Kulik, MD (USA)

• P-47: Benefits and Harms of Hepatocellular Carcinoma Surveillance in A Prospective Cohort of Patients with Cirrhosis

Amit G. Singal (USA)

• P-40: A Fucosylated Kininogen-Based Biomarker Panel Is Highly Accurate for Early Detection Hepatocellular Carcinoma in Patients with Cirrhosis: A Phase Iii Biomarker Evaluation

Anand Mehta (USA)

• P-103: Exposure-Response Analysis for Nivolumab + Ipilimumab Combination Therapy in Patients with Advanced Hepatocellular Carcinoma

Bruno Sangro (Spain)

• P-32: Standardized Sampling and Reporting Protocol Is the Key to Improve Microvascular Invasion Detection Rate

Lijuan Liu (China)



CEST TIME

16.05 - 16.35 • P-66: Overall Survival Is Impacted by Liver Failure and Co-Morbidities Rather Than Etiology Of Cirrhosis in Patients with Hepatocellular Carcinoma Detected During A Surveillance Program

Nathalie Ganne-Carrie (France)

• P-109: Post-Registration Experience of Nivolumab Therapy in Patients with Advanced Hepatocellular Carcinoma (Hcc): An International Study.

Petros Fessas (UK)

• P-115: Sequential Treatment with Sorafenib Followed by Regorafenib In Patients with Unresectable Hepatocellular Carcinoma (HCC): Interim Analysis of The Observational REFINE Study

Philippe Merle (France)

• P-03: Ramucirumab For Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy: Interim Results from An Expansion Cohort of The Phase 3 Reach-2 Study

Richard Finn (USA)

• P-56: Abnormal and Euthyroid Ranges of Thyroid Hormones in Serum and Liver Cancer Mortality: A Cohort Study

Won Sohn (Republic of Korea)

17.45 - 18.15 BEST BASIC / TRANSLATIONAL POSTER SESSION10 Top scored clinical e-Posters presenters will participate on this LIVE Q&A session where participants and specialists will ask poster presenters about findings described in their posterChair: Amaia Lujambio, PhD (USA))

• P-92: Characterization of Chromatin Accessibility in Hepatocellular Carcinoma Cells Using Single Cell Atac Sequencing

Amanda Craig (USA)

• P-81: Cold-Inducible Rna Binding Protein as A Vaccination Platform Against Hepatocellular Carcinoma

David Repáraz (Spain)

• P-91: Dual Targeting of Tumor Associated Macrophages and Immunosuppressive Granulocytic Myeloid-Derived Suppressor Cells Augments Pd-1 Blockade in Cholangiocarcinoma

Emilien Loeuillard (USA)



CEST TIME

17.45 - 18.15 • P-77: Identification of Neoantigen-Reactive Tumor-Infiltrating T Cell in Hepatocellular Carcinoma.

Enric Vercher Herraez (Spain) • P-86: Activated Peripheral Blood Lypmphocytes Of Hepatocellular Carcinoma Patients

(Hcc) Are Associated with Increased Risk of Early Dermatologic Adverse Effects During Sorafenib Treatment

Josep Corominas Argente del Castillo (Spain)

• P-76: Immune-Remodeling Effects of Lenvatinib Plus Anti-Pd1 In A Murine Model of Hepatocellular Carcinoma

Laura Torrens (Spain)

• P-70: Immunogenomic Characterization of Multifocal Liver Cancer Liangqing Dong (China)

• P-90: Implications of Notch3 Expression and Signaling For Cholangiocarcinogenesis Sarah Fritzsche (Germany)

• P-28: Purification and Digital Scoring of Extracellular Vesicles for Detection of Early-Stage Hepatocellular Carcinoma

Vatche Agopian (USA)

19.20 - 19.40 ILCA Junior Investigator Awards CeremonyChairs: ILCA President Bruno Sangro, MD, PhD (Spain)

ILCA Executive SecretaryAugusto Villanueva, MD, PhD (USA)

ILCA TreausurerSandrine Faivre, MD, PhD (France)

ILCA Past PresidentMorris Sherman, MD, PhD (Canada)


GlanceProgramme at a GlanceSATURDAY, 12TH SEPTEMBER 2020

CEST TIME

13.40 – 14.0013.40 – 14.00 HIGHLIGHTS OF THE DAY 1

A summary conversation capturing the first day programme of presentations, panel discussions and the interactive dialogue at the conference day. Augusto Villanueva, MD, Phd (USA)Laura Kulik, MD (USA)

15.00 - 16.0015.00 - 16.00GENERAL SESSION 1: MOLECULAR PATHOGENESIS, CELL BIOLOGY AND TRANSLATIONAL RESEARCH - Q&A

Chair: Jean Charles Nault, MD, PhD (France)Chair: Jean Charles Nault, MD, PhD (France)

• O-05: Lysyl Oxidase Shapes Physical and Metabolic Interactions Between Tumor And Stroma in Cholangiocarcinoma Patients

Monika Lewinska (Denmark)

• O-06: Supervised Learning Based on Tumor Imaging and Biopsy-Derived Transcriptomic Data Predicts Response of Hepatocellular Carcinoma to Transarterial

Geoffrey Fucile (Switzerland)

• O-07: Telomere Length Is A Major Determinant of Hepatocellular Carcinoma Diversity and A Therapeutic Target

Massih Ningarhari (France)

• O-08: Cooperation Between Distinct Cancer Driver Genes Underlies Inter-Tumor Heterogeneity in Hepatocellular Carcinoma

Amaia Lujambio (USA)

16.05 - 16.2016.05 - 16.20Q&A BASIC SCIENCE SYMPOSIUM: MOLECULAR PATHOGENESIS AND TARGETS IN CHOLANGIOCARCINOMA

15 minutes 15 minutes Q&AQ&A with the speakers and moderator. Participants will be able to ask questions with the speakers and moderator. Participants will be able to ask questions in writing using the Q&A box.in writing using the Q&A box.

Chair: Augusto Villanueva, MD, PhD (USA)Chair: Augusto Villanueva, MD, PhD (USA)

• Pathogenesis and molecular drivers of cholangiocarcinoma Gregory Gores, MD (USA)

• Novel therapeutic targets in cholangiocarcinoma: Beyond IDH Daniela Sia, PhD (USA)

• Biomarkers in cholangiocarcinoma Jesper B. Andersen, MD, PhD (Denmark)



CEST TIME

16.20 - 16.3516.20 - 16.35Q&A SEQUENCING AND STRATIFICATION OF SYSTEMIC THERAPY IN HCC SYMPOSIUM

15 minutes 15 minutes Q&AQ&A with the speakers and moderator. Participants will be able to ask questions with the speakers and moderator. Participants will be able to ask questions in writing using the Q&A box.in writing using the Q&A box.

Chairs: Lorenza Rimassa, MD (Italy), R. Kate Kelley, MD (USA) Chairs: Lorenza Rimassa, MD (Italy), R. Kate Kelley, MD (USA)

• The Growing Landscape of Systemic Therapies for Advanced HCC - The Second Line in a Dynamic Landscape Stephen Chan (Honk Kong)

• Expanding the Reach of Systemic Therapy in HCC - Novel Molecular Targets, Agents and Biomarkers for HCC Josep Maria Llovet (Spain/USA) • Endpoints for Systemic Therapy Trials in Advanced HCC:

Should Overall Survival be the Only Gold Standard in Expanding Treatment Landscape? - PRO: OS remains gold standard. Maria Reig (Spain) - CON: Surrogate endpoints are acceptable and necessary. Richard Finn (USA) • Systemic Therapy in Special Populations - HIV, dialysis, and autoimmune disease David Pinato (UK)

16.40 - 16.5516.40 - 16.55SINGLE TOPIC WORKSHOP Q&A ON "MOLECULAR DIVERSITY AND SYSTEMIC TREATMENT FOR HCC" AND "SURGERY IN THE MANAGEMENT OF HCC: ROLE OF SURGEONS AND OF THE RADIOLOGISTS"

15 minutes Q&A session with the speakers of the Single Topic Workshop and moderator. Participants will be able to ask questions in writing using the Q&A box. .

Chair : Jean-Claude Nault, MD, PhD (France)

• Molecular diversity and systemic treatment for HCC Amaia Lujambio, PhD (USA) Andrew Zhu, MD, PhD (USA)

• Surgery in the management of HCC: role of surgeons and the radiologists Riccardo Lencioni, MD (Italy) Eric Vibert, MD, PhD (France)



CEST TIME

16.55 - 17.1016.55 - 17.10 Q&A FOR ILCA SYMPOSIUM: CANCER CARE BEYOND ANTI-TUMOR THERAPY

15 minutes Q&A sessions with 2 speakers and moderator. Participants will be able to ask 15 minutes Q&A sessions with 2 speakers and moderator. Participants will be able to ask questions through the Q&A box..questions through the Q&A box..

Chair: Bruno Sangro, MD, PhD (Spain)Chair: Bruno Sangro, MD, PhD (Spain)

• Pshychooncology: Basic Principles applied to liver cancer Maria DieTrill, PhD (Spain)

• Management of cancer-treatment related Fatigue and cancer-related cachexia: Combine supportive, palliative, and rehabilitative care Florian Strasser, MD (Switzerland)

17.15 - 18.4517.15 - 18.45 GENERAL SESSION 2: EPIDEMIOLOGY, STAGING AND PROGNOSIS

Chair: Sasan Roayaie, MD, FACS. (USA)

• O-09: Prognostic Role of Pecs2 Index in Advanced Biliary Tract Cancer Patients Treated with First Line Chemotherapy: Training and Validation Cohorts.

Giulia Rovesti (Italy)

• O-10: Early Recurrence of Hepatocellular Carcinoma Following Transplantation: Risk Score from A Multi-Institutional Study Of > 3000 Patients

Parissa Tabrizian (USA)

• O-12: The Metroticket 2.0 And Afp Score Have Similar Performance to Predict Post-Lt Outcomes: Results of A Multinational Multicentre Cohort Study.

Federico Piñero (Argentina)

• O-13: Patient-Reported Barriers Are Associated with Hcc Surveillance Receipt in A Multi-Center Cohort of Patients with Cirrhosis

Amit G. Singal (USA)

• O-14: Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of An International Multicenter Analysis

Matthew Holzner (USA)

• O-15: A Multicenter, Cross-Section Study of The Impact of Covid-19 Pandemic on The Management of Hepatocellular Carcinoma A High-Prevalence French Area.

Giuliana Amaddeo (France)


GlanceProgramme at a GlanceSUNDAY, 13TH SEPTEMBER 2020

CEST TIME

13.40 – 14.0013.40 – 14.00 HIGHLIGHTS OF THE DAY 2

A summary conversation capturing the first day programme of presentations, panel discussions and the interactive dialogue at the conference day. Amaia Lujambio, PhD (USA)Augusto Villanueva, MD, PhD (USA)

15.00 - 16.3015.00 - 16.30 GENERAL SESSION 3: DIAGNOSIS, IMAGING AND BIOMARKERS

Chair: Amit Singal, MD (USA) Chair: Amit Singal, MD (USA)

• O-16: Construction and Implementation of An Artificial Intelligence Model for Microvascular Invasion Prediction of Hepatocellular Carcinoma

Han Xiao (China)

• O-17: Comparative Accuracy of Abbreviated Mri Vs. Ultrasound for Detection of Early-Stage Hcc In Patients with Cirrhosis

Takeshi Yokoo (USA)

• 0-18: Alpha-Fetoprotein (AFP) Kinetics as A Potential Surrogate Biomarker in Patients (Pts) With Hepatocellular Carcinoma (HCC) Treated with Atezolizumab (Atezo) + Bevacizumab (Bev)

Andrew X. Zhu (USA)

• O-19: Unannotated Small RNA In Circulating Extracellular Vesicles Detect Early Stage Liver Cancer

Johann von Felden (Germany)

• O-20: Improved Sensitivity for Early-Stage Hepatocellular Carcinoma Detection with A Novel Blood-Based Panel of Methylated Dna And Protein Markers

Amit Singal (USA)

• O-21: Inflammatory and Insulinemic Potential of Diet And Lifestyle With Risk Of Hepatocellular Carcinoma

Xuehong Zhang (USA)

16.35 - 16.5016.35 - 16.50 Q&A ILCA SYSTEMIC THERAPY GUIDANCE

15 minutes Q&A with speakers and moderator. Participants will be able to ask questions in 15 minutes Q&A with speakers and moderator. Participants will be able to ask questions in writing using a Q&A chat box.writing using a Q&A chat box.

Tim Meyer, MD, PhD (UK)Tim Meyer, MD, PhD (UK)R. Kate Kelley, MD (USA)R. Kate Kelley, MD (USA)


GlanceProgramme at a GlanceSUNDAY, 13TH SEPTEMBER 2020

CEST TIME

16.50 - 17.0516.50 - 17.05 Q&A ILCA BIOMARKER DEVELOPMENT IN HCC GUIDANCE

15 minutes Q&A with speakers and moderator. Participants will be able to ask questions in 15 minutes Q&A with speakers and moderator. Participants will be able to ask questions in writing using a Q&A chat box.writing using a Q&A chat box.

Augusto Villanueva, MD, PhD (USA)Augusto Villanueva, MD, PhD (USA)Amit Singal, MD (USA)Amit Singal, MD (USA)

17.10 - 18.4017.10 - 18.40 GENERAL SESSION 4: THERAPY AND CLINICAL TRIALS

Chair: Tim Meyer, MD, PhD (UK)

• O-22: The Novel Regimen of Tremelimumab In Combination with Durvalumab Provides a Favorable Safety Profile and Clinical Activity for Patients with Advanced

R. Katie Kelley (USA)

• O-23: Transarterial Chemoembolization and Radioembolization Are Similarly Effective in Achieving Successful Hepatocellular Carcinoma Downstaging In the Multicenter Evaluation of Reduction in Tumor Size Before Liver Transplantation (Merits-Lt) Consortium

Neil Mehta (USA)

• 0-24: Outcomes for Patients with Advanced Hepatocellular Carcinoma and Child-Pugh B Liver Function in The Phase 3 Celestial Study of Cabozantinib Versus Placebo

Anthony B. El-Khoueiry (USA)

• 0-25: Radiological and Pathological Response to Neoadjuvant Nivolumab In Patients with Bclc a Hcc Treated by Curative Percutaneous Irreversible Electroporation: Preliminary Report from The French Multicentre Phase 2 Nivolep Trial.

Pierre Nahon (France)

• O-26: Proton Beam Radiotherapy Versus Radiofrequency Ablation Treatment in Patients with Recurrent Hepatocellular Carcinoma: A Randomized Controlled Phase 3 Non-Inferiority Aproh Trial

Joong-Won Park (Republic of Korea)

• O:27: Nivolumab After Selective Internal Radiation Therapy (Sirt) Using Sir-Spheres Resin Microspheres in Patients with Hepatocellular Carcinoma: The Nasir-Hcc Trial

Bruno Sangro (Spain)

18.40 - 18.5018.40 - 18.50 FAREWELL ADDRESS

ILCA President, Bruno Sangro, MD, PhD (Spain) ILCA President, Bruno Sangro, MD, PhD (Spain)


PracticalitiesPracticalitiesABOUT THE CONFERENCE

▶ About ILCA

The International Liver Cancer Association (ILCA) is the only international organisation devoted exclusively to liver cancer research for experts from all related disciplines.

ILCA aims at creating an international multidisciplinary forum to address the increasing incidence of liver cancer through the enhancement of the knowledge of clinical, translational, and basic research, ultimately creating novel preventive, diagnostic and therapeutic strategies.

The purpose for which ILCA was established is the advancement of medical education, research, and clinical care in the field of liver cancer.

Please come and visit us at the ILCA stand. The ILCA Team will be pleased to meet you and provide you with any information you may wish to have on ILCA activities, membership, and future conferences.

▶ Accreditation

The International Liver Cancer Association’s 14th Annual Conference being the first ILCA virtual conference this year has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

▶ Junior Investigator Awards

ILCA will recognise extraordinary achievements in liver cancer research across disciplines and support the professional development of four junior investigators in training. The awards will be given for novel and significant liver cancer research across the fields of basic cancer research; translational cancer research; cancer diagnosis; the prevention of cancer; or cancer patients treatment.

The investigators who submit the best clinical oral and best poster presentations and the best basic-translational oral and best poster presentations will be honoured LIVE on Friday, 11 September 2020 at 19:20 CEST.

▶ Official Language

The official language of the conference is English. Simultaneous translation will not be provided.

Information is also available at www.ilca-online.org Intern a tional Liver Cancer A s soci at io n

https://ilca-online.org/membership/


PartnersSponsors, Media and other PartnersILCA warmly thanks all the Partners and Supporters for their involvement in ILCA 2020.

Partners & SupportersPrincipal Partners

Supporters

Conference Partners


PartnersSponsors, Media and other PartnersMedia Partners

Partner Societies

• American Association for the Study of Liver Diseases (AASDL) • American Society of Clinical Oncology (ASCO) • Asian Pacific Association for the Study of the Liver (APASL)• Asia-Pacific Primary Liver Cancer Expert Association • Canadian Association of Gastroenterology (CAG) • Canadian Association for the Study of the Liver (CASL) • European-African Hepato-Pancreato-Biliary Association (E-AHPBA) • European Association for Cancer Research (EACR) • European Association for the Study of the Liver (EASL) • European Society for Medical Oncology (ESMO)• European Society of Surgical Oncology (ESSO) • International Liver Transplantation Society (ILTS) • Japan Society of Clinical Oncology (JSCO) • Japanese Society of Medical Oncology (JSMO)• Korean Association for Clinical Oncology (KACO)• Korean Association for the Study of the Liver (KASL)• Korean Cancer Association (KCA)• Korean Liver Cancer Association (KLCA)• Korean Association of Hepato-Biliary-Pancreatic Surgery (KAHBPS)• Society of Interventional Oncology (SIO)• Stockholm Liver Week• United European Gastroenterology (UEG)


ILCAAbout ILCA▶ Genesis

Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no single association has before the International Liver Cancer Association (ILCA) adopted a transversal approach to liver cancer by connecting expertise from interrelated fields, research, and treatment levels. In response to this shortfall, ILCA was established in 2006 and is currently the only international organisation devoted exclusively to liver cancer across disciplines.

▶ Our Mission

ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by promoting novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking a transversal approach to research. Indeed, ILCA brings together scientists, physicians and allied professionals from all interrelated fields and countries and strives to welcome and incorporate individuals involved in all the scientific disciplines devoted to basic, translational and clinical research in liver cancer as individual members. ILCA actively partners with other professional associations involved in any aspect related to liver cancer research, with the objective to join efforts for the benefit of science.

▶ Joining Our Community

We invite you to discover more about ILCA on www.ilca-online.org, as well as to connect with our expanding group of interested physicians, scientists, and allied health professionals from various fields and from around the world. Membership to ILCA not only provides you with exclusive benefits such as reduced registration rates to our Annual Conferences, exciting networking and educational opportunities and active involvement in association affairs; it also helps us to develop our activities and our reach to advance liver cancer research and care.

▶ ILCA Governing Board

Executive Committee Council Contact us

PresidentBruno Sangro (Spain)

Joong-Won Park (Republic of Korea)Sasan Roayaie (USA)Laura Kulik (USA) Jeong Min Lee (Republic of Korea)Amit Singal (USA)Eric Vibert (France)Tim Meyer (UK)Amaia Lujambio (USA)Michiie Sakamoto (Japan)Jean-Charles Nault (France)R. Kate Kelley (USA)

Association (ILCA)Boulevard du Souverain, 280B-1160 Brussels – BelgiumTel:+32 (0)2 320 [email protected]

Executive SecretaryAugusto Villanueva (USA)

TreasurerSandrine Faivre (France)

Past President Morris Sherman (Canada)


SymposiaPartner SymposiaFRIDAY, 11TH SEPTEMBER 2020

14.00 - 15.0014.00 - 15.00 ROCHE INDUSTRY PARTNER SYMPOSIUM

How could treatment practice change with cancer immunotherapy combinations in patients with HCC?

In this symposium an esteemed panel will provide an overview of the evolving treatment landscape for HCC, review the most recent data for cancer immunotherapy combinations in patients with unresectable HCC and, crucially, provide expert insights and guidance on how their safety profiles can be navigated.

• Navigating the shifting treatment patterns for HCC• Understanding the latest efficacy data for unresectable HCC• Discussing safety with cancer immunotherapy combinations• Making the correct clinical decisions: what do we need to know?• Reviewing a patient case: who are the right patients for cancer immunotherapy

combinations?

Speakers:

Peter Galle, University Medical Centre, Mainz, GermanyRiccardo Lencioni, Director of the Division of Diagnostic Imaging and Intervention in the Department of Hepatology and Liver Transplantation Pisa University Hospital, Italy Bruno Sangro, Director of the Liver Unit and Co-Director of the HPB Oncology Area Clínica Universidad de NavarraJian Zhou, Zhongshan Hospital, China

This symposium is intended only for physicians practicing outside the USA!

16.40 - 17.4016.40 - 17.40 IPSEN INDUSTRY PARTNER SYMPOSIUM

Changing the disease course in HCC, current evidence and future insights

This symposium will provide an update on the most recent data on HCC treatment, within the context of the rapidly evolving treatment landscape. As well as discussing the latest clinical data surrounding treatment sequencing to achieve optimal outcomes for patients.

Finally, looking to the future, how application of the latest preclinical and clinical data may shape future treatment strategies, with an overview of combinations currently under investigation, and implications for the future of HCC treatment.

• Translating latest clinical trials evidence into treatment decisions• Sequencing of systemic therapy in today’s clinical practice• Insights from the tumour microenvironment for the 2021 treatment landscape

Partner Symposia at ILCA 2020 give you the chance to discuss and exchange knowledge on data and products with our industry partners.


SymposiaPartner SymposiaFRIDAY, 11TH SEPTEMBER 2020

16.40 - 17.4016.40 - 17.40 IPSEN INDUSTRY PARTNER SYMPOSIUM

Speakers:

Sandrine Faivre, Professor Medical Oncology, Hôpital St-Louis, FranceJosep Maria Llovet, Professor IDIBAPS-HOSPITAL CLÍNIC / ICAHN School of MedicineArndt Vogel, Professor for gastrointestinal oncology, Hannover Medical School

This is an educational, non-promotional meeting organised and funded by Ipsen. The opinion and views expressed in this presentation are those of the presenter and do not necessarily constitute the opinions or recommendations of Ipsen (i.e. The scientific information may include data/information on drugs that have not yet received price and reimbursement approval by local regulatory authorities). CBZ-ALL-002167/CBZ-BE-000412Date of preparation: August 2020

18.20 - 19.2018.20 - 19.20 INCYTE INDUSTRY PARTNER SYMPOSIUM

Personalised Approaches in Cholangiocarcinoma

What is the best way to navigate the genomic diversity of cholangiocarcinoma? How do clinicians ensure patients with cholangiocarcinoma receive the most appropriate treatment tailored to their individual needs?

These are the key questions addressed by four leading cholangiocarcinoma experts, as they share experiences and practical guidance on a precision medicine-based approach during this educational symposium.

• Cholangiocarcinoma: Not a single disease• Cholangiocarcinoma molecular characterisation: Challenges and opportunities• Cholangiocarcinoma clinical research: What’s new?

Speakers:

Bruno Sangro, Director of the Liver Unit and Co-Director of the HPB Oncology Area Clínica Director of the Liver Unit and Co-Director of the HPB Oncology Area Clínica Universidad de NavarraUniversidad de NavarraDr. Harpreet Wasan, London, UK London, UKDr. Ana Vivancos, Barcelona, SpainBarcelona, SpainDr. Joachim Mertens, Zurich, Switzerland Zurich, Switzerland

Continued form page18


SymposiaPartner SymposiaSATURDAY, 12TH SEPTEMBER 2020

14.00 - 15.0014.00 - 15.00 EISAI INDUSTRY PARTNER SYMPOSIUM

The evolving HCC treatment landscape: what is the role of LENVIMA® monotherapy in first-line uHCC?

In this symposium, Professor Andrew Zhu and Professor Arndt Vogel will discuss the role of LENVIMA® monotherapy in the rapidly evolving uHCC treatment landscape. This will include discussions around patient selection and clinical considerations in the first line setting as well as an overview of the latest clinical data for LENVIMA® monotherapy.

• The role of LENVIMA® monotherapy in first-line uHCC• What did we learn when results for REFLECT were released?• What have we learnt following REFLECT?

Speakers:

Professor Andrew Zhu, Professor of Medicine at Harvard Medical School and Director Professor of Medicine at Harvard Medical School and Director Emeritus of Liver Cancer Research at Massachusetts General Hospital and Director, Jiahui Emeritus of Liver Cancer Research at Massachusetts General Hospital and Director, Jiahui International Cancer Center, Shanghai, ChinaInternational Cancer Center, Shanghai, ChinaProfessor Arndt Vogel, Professor for gastrointestinal oncology at the Hannover Medical Professor for gastrointestinal oncology at the Hannover Medical SchoolSchool

The materials for LENVIMA® produced by Eisai for this virtual conference are approved for UK healthcare professionals and other relevant decisions makers. LENVIMA® is indicated in the UK as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

For the full UK prescribing information, go to the following link: eisaihcc.com. Prescribing information may vary depending on local approval for each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Prescribing Characteristics (SPC).

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for the MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events should also be reported to Eisai Ltd on +44 (0)845 676 1400/ +44 (0)208 600 1400 or [email protected]


SymposiaPartner SymposiaSUNDAY, 13TH SEPTEMBER 2020

14.00 - 15.0014.00 - 15.00 BOSTON SCIENTIFIC INDUSTRY PARTNER SYMPOSIUM

Y90: A Step Towards Curative Therapies for HCC

Join Boston Scientific symposium to learn more about the 15-year, 207 patient experience on SIRT.

• Long Term Outcomes of Liver Transplant Following Y90 • SIRT for Downstaging • Positioning SIRT in the Treatment Algorithm

Speakers:

Dr Talia Baker, Dr Talia Baker, Transplant Surgeon, University of Chicago, USATransplant Surgeon, University of Chicago, USADr Peter Littler, Dr Peter Littler, Interventional Radiologist, Freeman Hospital, UK Interventional Radiologist, Freeman Hospital, UK Dr Julien Edeline, Dr Julien Edeline, Medical Oncologist, Centre Eugene Marquis, FranceMedical Oncologist, Centre Eugene Marquis, France

HCP based in France should be aware of the following statement:

Il est recommandé aux médecins basés en France de consulter les instructions suivantes: Les informations disponibles sur la page Boston Scientific sont destinées au public international de professionnels de santé assistant au congrès ILCA et ne sont pas spécifiquement destinés aux professionnels de santé exerçant en France, n’étant donc pas soumis à l’obligation de mise en conformité à la loi française relative à la publicité des dispositifs médicaux.

Pour obtenir la documentation en français, mentions obligatoires et fiches techniques, merci d’adresser vos demandes à [email protected] Dispositifs médicaux, consultez les notices spécifiques à chacun pour plus d’information.

▶ Index of Authors

The Index of Authors lists all abstract authors in alphabetical order. To locate the page of the abstract, first take note of the abstract number (Example: P-002) and then locate the abstract, listed by type of presentation and in sequential order, in the table of contents, where you will find a reference for the page number.

▶ Disclaimer

This Book of Abstracts has been produced using author-supplied copies. Editing has been restricted to minor spelling corrections where appropriate, otherwise every effort has been made to reproduce the abstracts as originally submitted. The organiser and publishers assume no responsibility for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. In view of rapid advances in medical sciences, independent verification of diagnoses and drug doses is recommended.

▶ www.ilca-online.org▶ www.ilca2020.org
http://www.ilca-online.orghttp://www.ilca2020.org

programme - ilca 2020 · 2020. 9. 11. · david rep áraz (spain) • p ... riccardo lencioni, md...

Documents